Sodium Carbonate → 3-[6-isopropyl-9-(1-methyl-1H-pyrazol-4-yl)-1-oxo-1,2-dihydrobenzo[c]-1,6-naphthyridin-4-yl]prop-2-ynamide
Reaction equation
Br[C:2]1[CH:24]=[CH:23][C:5]2[C:6]([CH:20]([CH3:22])[CH3:21])=[N:7][C:8]3[C:9]([C:15]#[C:16][C:17]([NH2:19])=[O:18])=[CH:10][NH:11][C:12](=[O:14])[C:13]=3[C:4]=2[CH:3]=1.[CH3:25][N:26]1[CH:30]=[C:29](B2OC(C)(C)C(C)(C)O2)[CH:28]=[N:27]1.C1C=CC(P(C2C=CC=CC=2)CCCP(C2C=CC=CC=2)C2C=CC=CC=2)=CC=1.C(Cl)Cl.C(=O)([O-])[O-].[Na+].[Na+]>Cl[Pd]Cl.CN(C=O)C>[CH:20]([C:6]1[C:5]2[CH:23]=[CH:24][C:2]([C:29]3[CH:28]=[N:27][N:26]([CH3:25])[CH:30]=3)=[CH:3][C:4]=2[C:13]2[C:12](=[O:14])[NH:11][CH:10]=[C:9]([C:15]#[C:16][C:17]([NH2:19])=[O:18])[C:8]=2[N:7]=1)([CH3:21])[CH3:22]Participants
Reactant 4
Product 1
Reagents, catalysts & solvents 2
Conditions
- Temperature
- 100 °C
Procedure
3-(9-bromo-6-isopropyl-1-oxo-1,2-dihydrobenzo[c]-1,6-naphthyridin-4-yl)prop-2-ynamide (57 mg, 0.15 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (62 mg, 0.30 mmol), and PdCl2(dppp-CH2Cl2 adduct (24 mg, 0.030 mmol) were added to a vial, followed by DMF (1.8 ml) and aqueous sodium carbonate (2M) (0.15 ml, 0.30 mmol). The resulting suspension was purged with argon (subsurface bubbling) for 10 min, then heated in a microwave reactor at 100° C. for 30 min. The mixture was cooled, diluted with DMF, and filtered to remove salts. The solution was purified directly by preparative reverse phase HPLC eluting with an acetonitrile/water (with 0.05% TFA as a modifier) gradient, to afford 3-[6-isopropyl-9-(1-methyl-1H-pyrazol-4-yl)-1-oxo-1,2-dihydrobenzo[c]-1,6-naphthyridin-4-yl]prop-2-ynamide. 1H NMR (500 MHz, DMSO-D6) δ 12.15 (br s, 1H), 10.15 (s, 1H), 8.46 (d, 1H), 8.34 (s, 1H), 8.01-7.98 (overlapping m, 3H), 7.89 (br s, 1H), 7.56 (br s, 1H), 4.08 (septet, 1H), 3.92 (s, 3H), 1.41 (d, 6H). LRMS (ESI) calc'd for (C22H19N5O2) [M+H]+, 386.2; found 386.1.
Workup
- customThe resulting suspension was purged with argon (subsurface bubbling) for 10 min
- temperatureThe mixture was cooled
- additiondiluted with DMF
- filtrationfiltered
- customto remove salts
- customThe solution was purified directly by preparative reverse phase HPLC
- washeluting with an acetonitrile/water (with 0.05% TFA as a modifier) gradient
Sources & evidence
- ORD record
- ord-833670c25b884cabbb056b97224ad00d
- Source dataset
- uspto-grants-2012_12
- Patent number
- US08329722B2
Reaction notes
Loading…